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The relationship between resistance to rifampicin
and rifabutin and genetic alterations in the rpoB
gene of 41 rifampicin-resistant isolates of Myco-
bacterium tuberculosis was evaluated. Although 35
isolates with rifampicin MICs ‡ 32 mg ⁄L were
also rifabutin-resistant, six isolates with rifampi-
cin MICs of 2–16 mg ⁄L were susceptible to rifabu-
tin (MIC £ 0.5 mg ⁄L). Mutations Asp516Val,
Asp516Tyr, Leu533Pro and the double mutation
Met515Ile and Leu533Pro influenced susceptibil-
ity to rifampicin, but not to rifabutin. All muta-
tions at codons 531 and 526, except one isolate
with a His526Cys mutation, correlated with resist-
ance to both compounds.
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Multidrug-resistant Mycobacterium tuberculosis
isolates have been described worldwide, and
their existence poses a serious threat to tubercu-
losis control programmes in many countries [1,2].
The development of more active and safe anti-
tuberculosis agents as alternatives to rifampicin
and isoniazid is therefore a high priority [3,4].
DNA sequencing studies demonstrate that > 90%
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of rifampicin-resistant strains have a mutation in
a hot-spot region of the RNA polymerase
b-subunit (rpoB) gene [5,6]. Rifabutin is a semi-
synthetic spiro-piperidyl derivative of rifamycin
S, which is more active than rifampicin against
slow-growing mycobacteria, including M. tuber-
culosis and members of the Mycobacterium avium–
intracellulare complex, both in vitro and in vivo
[7–9]. Many studies have confirmed that rifabutin
is also active against some rifampicin-resistant
M. tuberculosis strains [10–14], but there are few
studies evaluating the relationship between rifab-
utin susceptibility and genetic alterations in the
M. tuberculosis rpoB gene. The present study
aimed to determine the MICs of rifabutin and
rifampicin for 41 rifampicin-resistant M. tubercu-
losis isolates of known rpoB sequence, and to
correlate the level of resistance with specific
genetic alterations in the rpoB gene.
Rifabutin and rifampicin were dissolved in
methanol and dimethylsulphoxide, respectively,
at concentrations of 10 mg ⁄mL. Stock solutions
were stored at ) 70C. Working solutions were
prepared by dilution in sterile distilled water [15].
The 41 rifampicin-resistant M. tuberculosis isolates
used in this study were obtained from the sputum
of 41 patients at the Regional Tuberculosis Labor-
atory and Ege University Mycobacteriology
Laboratory, Izmir, Turkey. Susceptibility to rifab-
utin and rifampicin was determined by the
proportional method on 7H10 medium, with the
critical concentrations for rifabutin and rifampicin
considered to be 0.5 mg ⁄L and 1 mg ⁄L, respect-
ively [15]. The standard strain M. tuberculosis
H37Rv was used as a control. Mutations in the
rpoB gene for each isolate had been determined
previously [16].
While 35 of the 41 rifampicin-resistant isolates
with MICs ‡ 32 mg ⁄L were also resistant to
rifabutin, six isolates with MICs of 2–16 mg ⁄L
were susceptible to rifabutin (Table 1). Previ-
ously, several groups of investigators [10,12–
14,17–19] have studied clinical isolates of
M. tuberculosis in order to gain an understanding
of the relationship between the MICs of rifamyc-
ins and rpoB mutations. Although different sus-
ceptibility testing methods have been used, and
some discrepancies have been reported, such
studies have generally revealed a strong correla-
tion between certain rpoB mutations and the MICs
of rifampicin and rifabutin. According to these
previous studies, all rifampicin-resistant isolates
with Asp516Val or Asp516Tyr substitutions were
susceptible to rifabutin, with the exception of two
isolates reported by Yuen et al. [14] with MICs of
> 1 mg ⁄L. In the present study, three isolates with
Asp516Val or Asp516Tyr substitutions were also
found to be rifabutin-susceptible. Rifampicin-
resistant isolates with His526Tyr, His526Asp,
His526Arg or His526Pro substitutions and muta-
tions at codons 513 and 531 were almost always
resistant to rifabutin. However, two isolates with
a Ser531Leu mutation were reported as rifabutin-
susceptible by Yang et al. [13] and Yuen et al. [14].
In the present study, all isolates with the muta-
tions mentioned above were resistant to rifabutin.
In general, isolates with mutations at codons
513 and 531, or with His526Asp, His526Arg,
His526Tyr or His526Pro mutations, have high-
level (MIC > 32 mg ⁄L) resistance to rifampicin.
However, two isolates with His526Arg mutations,
one isolate with a His526Tyr mutation and one
isolate with a Ser531Leu mutation were shown to
have low-level (MIC £ 32 mg ⁄L) resistance to
rifampicin by Hwang et al. [17]. In addition, two
isolates with a Gln513Pro mutation and one
isolate with a Gln513Leu mutation were shown
to have low-level rifampicin resistance by Wil-
liams et al. [12]. In the present study, two isolates
with a Ser531Leu mutation also had low-level
rifampicin resistance (MICs of 32 mg ⁄L).
Although minor discrepancies have been repor-
ted [13,14], in general a correlation exists between
the MICs of rifampicin and rifabutin. Isolates with
Table 1. Relationship between MICs of rifampicin and
rifabutin and genetic alterations in rifampicin-resistant
Mycobacterium tuberculosis isolates
No. of strains
MIC (mg ⁄L)
Sequencing
results
Amino-acid
change(s)Rifampicin Rifabutin
1 > 128 > 5 513 CAA ﬁ CCA Gln ﬁ Pro
1 > 128 > 5 522 TCG ﬁ TGG Ser ﬁ Trp
1 > 128 > 5 526 CAC ﬁ GAC His ﬁ Asp
2 > 128 > 5 526 CAC ﬁ TAC His ﬁ Tyr
4 > 128 > 5 526 CAC ﬁ CGC His ﬁ Arg
4 > 128 > 5 531 TCG ﬁ TGG Ser ﬁ Trp
15 > 128 > 5 531 TCG ﬁ TTG Ser ﬁ Leu
1 128 > 5 490 CAG ﬁ CAT Gln ﬁ His
1 128 > 5 522 TCG ﬁ TGG Ser ﬁ Trp
1 128 > 5 531 TCG ﬁ TTG Ser ﬁ Leu
1 64 2.5 531 TCG ﬁ TTG Ser ﬁ Leu
1 32 5 514 515 ins. CGG Arg
1 32 5 531 TCG ﬁ TTG Ser ﬁ Leu
1 32 1 531 TCG ﬁ TTG Ser ﬁ Leu
2 16 0.5 516 GAC ﬁ TAC Asp ﬁ Tyr
1 8 0.5 516 GAC ﬁ GTC Asp ﬁ Val
1 8 0.125 515 ATG ﬁ ATC
533 CTG ﬁ CCG
Met ﬁ Ile
Leu ﬁ Pro
1 2 0.5 533 CTG ﬁ CCG Leu ﬁ Pro
1 2 0.0625 526 CAC ﬁ TGC His ﬁ Cys
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high-level rifampicin resistance are almost always
resistant to rifabutin. Moreover, such isolates
generally show high-level (MIC > 4 mg ⁄L)
resistance to rifabutin. In the present study, a
clear correlation was also determined between
high-level resistance to rifampicin and resistance
to rifabutin.
The same mutation in the same codon in the
hot-spot region does not always result in the
same level of resistance. While Hwang et al. [17]
and Williams et al. [12] have reported high-level
rifampicin resistance in isolates with the Leu533-
Pro mutation, Ohno et al. [19] and Yang et al. [13]
found low-level resistance. Furthermore, one
isolate with a Leu533Pro mutation was found
to be rifampicin-susceptible by Yang et al. [13]. In
the present study, two isolates with the Leu533-
Pro mutation showed low-level resistance to
rifampicin, but retained their susceptiblity to
rifabutin. These findings suggest that some addi-
tional factor(s) might contribute to variations in
drug resistance [20]. In particular, different
mutations in the same codon did not always
reflect the same level of drug resistance. While
isolates with Ser522Gln and Ser522Leu mutations
have been reported to be rifabutin-susceptible
[10,12,14], the present study revealed two isolates
with a Ser522Trp mutation that were resistant to
rifabutin. In addition, while certain mutations at
codon 526, including His526Tyr, His526Asp,
His526Arg and His526Pro, usually result in
rifabutin resistance, isolates with His526Leu,
His526Gly or His526Gln mutations were suscept-
ible to rifabutin. In the present study, one isolate
with a His526Cys mutation was found to have
low-level rifampicin resistance, but was highly
susceptible to rifabutin.
In addition to DNA sequencing of the rpoB
gene, rapid line probe assays (LIPA Rif) can detect
point mutations within the 81-bp region of the
rpoB gene that includes Ser531Leu, His526Asp,
His526Tyr and Asp516Val [16]. Such assays might
be useful for predicting rifampicin susceptibility
and for deciding when to use rifabutin for treating
tuberculosis.
In conclusion, all strains resistant to rifabutin
were also cross-resistant to rifampicin. However,
rifabutin remained active against rifampicin-
resistant strains with certain genetic alterations.
The precise relationship between amino-acid
substitions in the ribosomal polymerase b-sub-
unit and resistance to rifamycins will be under-
stood properly only when the three-dimensional
crystal structure of the b-subunit has been
elucidated.
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Between January 1993 and December 2001, the
overall frequency of resistance to third-generation
cephalosporins in isolates of Enterobacteriaceae
from Charles Nicolle Hospital, Tunis, rose from
2.4% to 7.4%. Klebsiella pneumoniae was the most
prevalent species (56%), followed by Escherichia
coli (15%) and Proteus mirabilis (9%). A rate of
49% was observed among isolates from paediat-
ric patients in 1999, caused mostly by outbreaks in
the neonatal intensive care unit of K. pneumoniae
and P. mirabilis isolates that produced extended-
spectrum b-lactamases.
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Acquired resistance to third-generation cephalo-
sporins among different species of enterobacteria
has become a growing problem worldwide [1,2].
Such resistance is often associated with transfer-
able plasmid-encoded class A extended-spectrum
b-lactamases (ESBLs) [1,2]. ESBL-producing
organisms are resistant to all b-lactams except
cephamycins and carbapenems. Since 1988, resist-
ance to cephamycins and broad-spectrum
cephalosporins has also appeared in enterobacte-
ria following the transfer of chromosomal genes
for inducible AmpC-type b-lactamases on to plas-
mids [3]. Unlike that of class A ESBLs, the activity
of AmpC-type b-lactamases is not inhibited by
clavulanic acid [4,5]. In addition, organisms pro-
ducing these enzymes are often resistant to many
other classes of antibiotics, including aminoglyco-
sides, tetracyclines, chloramphenicol, trimetho-
prim–sulphonamides and fluoroquinolones [3,4].
The prevalence of acquired resistance to third-
generation cephalosporins varies from country to
country [1–3,5]. In Tunisia, the first ESBL-produ-
cing isolate (of Klebsiella pneumoniae) was reported
at Charles Nicolle Hospital in 1984 [6,7], and the
first plasmid-mediated AmpC-type b-lactamase
was identified in 1996 in an isolate of Proteus
mirabilis [8]. Subsequently, resistance to third-
generation cephalosporins was found in different
species of enterobacteria causing nosocomial out-
breaks, with serious problems resulting for anti-
microbial therapy [7,9]. To evaluate the extent of
this type of resistance at Charles Nicolle Hospital,
and to strengthen control measures, a surveillance
programme was carried out.
During the period January 1993 to December
2001, 22 691 isolates of enterobacteria were
obtained from hospitalised patients in different
wards of Charles Nicolle Hospital, a 1000-bed
teaching hospital. All isolates were identified
using the API 20E system (bioMe´rieux, Marcy
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